Dermatologic infections in cancer patients treated with checkpoint inhibitors

The incidence of dermatologic infections in patients receiving checkpoint inhibitors (CPIs) has not been systematically described. Identify the incidence of dermatologic infections in patients who received CPIs. Retrospective review of dermatologic infections in patients who received CPIs between 20...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2021-12, Vol.85 (6), p.1528-1536
Main Authors: Do, Mytrang H., Barrios, Dulce M., Phillips, Gregory S., Postow, Michael A., Warner, Allison Betof, Rosenberg, Jonathan E., Noor, Sarah J., Markova, Alina, Lacouture, Mario E.
Format: Article
Language:English
Subjects:
anti-CTLA-4
anti-PD-1
anti-PD-L1
cancer
checkpoint inhibitors
dermatologic infections
Humans
Immune Checkpoint Inhibitors
Incidence
Neoplasms - drug therapy
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The incidence of dermatologic infections in patients receiving checkpoint inhibitors (CPIs) has not been systematically described. Identify the incidence of dermatologic infections in patients who received CPIs. Retrospective review of dermatologic infections in patients who received CPIs between 2005 and 2020 and were evaluated by dermatologists at Memorial Sloan Kettering Cancer Center. Of 2061 patients in the study, 1292 were actively receiving CPIs (≤ 90 days since the last dose) and 769 had previously been on CPIs (> 90 days since the last dose). The dermatologic infection rate was significantly higher in patients with active CPI treatment (17.5%) than in patients not actively being treated (8.2%; P 
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2021.03.039